The US Court of Appeals for the Federal Circuit affirmed a district court’s delisting of patents from the Orange Book because the patent claims ...

The complaint alleges nearly two dozen pharmaceutical companies colluded to limit competition, causing costs for certain ...

Gujarat-based drugmaker Intas Pharmaceuticals Ltd., which counts private equity firm ChrysCapital, Singapore state ...

Teva Pharmaceutical (NYSE ... “Teva's innovative branded drugs and biosimilar pipeline, including AUSTEDO and upcoming biosimilars like PROLIA and RANIVISIO, offer substantial growth ...

Teva Pharmaceutical is the leading generic drug manufacturer in the world. By our estimate, roughly 70% of its total sales are derived from generics and off-patent branded drugs. The firm ...

Teva Pharmaceuticals and Sanofi also reported ... Thanks to the increased share of sales of its branded drugs, as well as the more than successful development of its next-generation product ...

The case is Teva Branded Pharmaceutical Products R&D Inc v. Amneal Pharmaceuticals of New York LLC, U.S. Court of Appeals for the Federal Circuit, No. 24-1936.

For branded drugmakers, the development of a pharmaceutical product approved by the Food and Drug Administration (FDA) all ...

Teva Pharmaceutical (NYSE:TEVA) shares rose for seven straight sessions, as the stock closed about 1% higher at $22.42 on Tuesday. The Israeli drugmaker stock added 34.5% in the preceding six sessions ...

Hikma’s branded generic will compete with Teva Pharmaceuticals authorized generic of Victoza in the United States that was launched earlier this year. Authorized generics are the exact copies ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease. Teva Pharmaceutical sees more growth in 2025 after strong Q3 November 6, 2024 Teva ...